Magazine Article | February 1, 2019

Why Patent Protection Is Key To Commercializing Repurposed Drugs

Source: Life Science Leader

By John Conour

If you’ve been involved in any aspect of drug development in your career, it’s likely you are aware that, on average, only 1 in 10 therapeutic candidates that enter Phase 1 clinical trials is approved. Consequently, the industry is littered with abandoned, shelved drugs, or drugs simply listed as “failures.”

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader